Browse GBP4

Summary
SymbolGBP4
Nameguanylate binding protein 4
Aliases Mpa2; GBP-4; GTP-binding protein 4; guanine nucleotide-binding protein 4; Guanylate-binding protein 4
Chromosomal Location1p22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Nucleus Cytoplasm, perinuclear region Golgi apparatus membrane Note=Heterodimers with GBP1, GBP2 and GBP5 localize in the compartment of the prenylated GBPs: with GBP1 in a vesicle-like compartment, with GBP2, around the nucleus and with GBP-5, at the Golgi apparatus.
Domain PF02263 Guanylate-binding protein
PF02841 Guanylate-binding protein
Function

Binds GTP, GDP and GMP. Hydrolyzes GTP very efficiently; GDP rather than GMP is the major reaction product. Plays a role in erythroid differentiation (By similarity).

> Gene Ontology
 
Biological Process -
Molecular Function GO:0003924 GTPase activity
GO:0005525 GTP binding
GO:0019001 guanyl nucleotide binding
GO:0032561 guanyl ribonucleotide binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04621 NOD-like receptor signaling pathway
Reactome R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-168256: Immune System
R-HSA-913531: Interferon Signaling
R-HSA-877300: Interferon gamma signaling
Summary
SymbolGBP4
Nameguanylate binding protein 4
Aliases Mpa2; GBP-4; GTP-binding protein 4; guanine nucleotide-binding protein 4; Guanylate-binding protein 4
Chromosomal Location1p22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between GBP4 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolGBP4
Nameguanylate binding protein 4
Aliases Mpa2; GBP-4; GTP-binding protein 4; guanine nucleotide-binding protein 4; Guanylate-binding protein 4
Chromosomal Location1p22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of GBP4 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolGBP4
Nameguanylate binding protein 4
Aliases Mpa2; GBP-4; GTP-binding protein 4; guanine nucleotide-binding protein 4; Guanylate-binding protein 4
Chromosomal Location1p22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of GBP4 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0690.924
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.4760.79
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.2230.868
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.680.0458
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.9310.593
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.3630.869
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.9990.0699
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.4640.361
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.3710.848
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 482.1830.178
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 282.3930.334
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.330.0404
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of GBP4 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.41.460.177
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.41.75.70.231
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.67.4-4.80.565
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.57.7-3.21
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolGBP4
Nameguanylate binding protein 4
Aliases Mpa2; GBP-4; GTP-binding protein 4; guanine nucleotide-binding protein 4; Guanylate-binding protein 4
Chromosomal Location1p22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of GBP4. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolGBP4
Nameguanylate binding protein 4
Aliases Mpa2; GBP-4; GTP-binding protein 4; guanine nucleotide-binding protein 4; Guanylate-binding protein 4
Chromosomal Location1p22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of GBP4. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by GBP4.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolGBP4
Nameguanylate binding protein 4
Aliases Mpa2; GBP-4; GTP-binding protein 4; guanine nucleotide-binding protein 4; Guanylate-binding protein 4
Chromosomal Location1p22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of GBP4. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolGBP4
Nameguanylate binding protein 4
Aliases Mpa2; GBP-4; GTP-binding protein 4; guanine nucleotide-binding protein 4; Guanylate-binding protein 4
Chromosomal Location1p22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of GBP4 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolGBP4
Nameguanylate binding protein 4
Aliases Mpa2; GBP-4; GTP-binding protein 4; guanine nucleotide-binding protein 4; Guanylate-binding protein 4
Chromosomal Location1p22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between GBP4 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolGBP4
Nameguanylate binding protein 4
Aliases Mpa2; GBP-4; GTP-binding protein 4; guanine nucleotide-binding protein 4; Guanylate-binding protein 4
Chromosomal Location1p22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting GBP4 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.